Daniel V.T. Catenacci, 45, entered a plea agreement in April after admitting he used insider knowledge about a positive global trial by Five Prime Therapeutics Inc. on its leading cancer drug Dr. Daniel Catenacci, 45, was charged in a criminal information filed in U.S. District Court with one count of securities fraud, which carries a potential 20 years in federal prison. Daniel V T Catenacci 316 Background: 5FU, Ox, Iri, and Tax are each active in upper GI cancers. Triplet cytotoxic therapies (txs) improved survival compared to doublets/singlets. Daniel Catenacci, MD, discusses recent updates in gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma. In November 2020, Dr. Catenacci used material, non-public information about the trial results to make more than $134,000 in illegal profits from the purchase and sale of securities in the company, according to a criminal information filed Friday in U.S. District Court in Chicago. Dr. Catenacci purchased more than 8,000 shares before the company Daniel V.T. Catenacci has held positions at the University of Chicago Medicine for over 15 years, starting as a fellow in Hematology and Medical Oncology from 2006 to 2010. He then joined the faculty at the University of Chicago as an Instructor in the Department of Medicine from 2010 to June 2012 before becoming an Assistant Professor of Medicine. Daniel Catenacci, an associate professor of medicine in the Biological Sciences Division, was charged with insider trading on Monday, December 20, 2021. The charge alleged that he used confidential information gained through his position at the University to make over $134,000 in illegal profits. He pled not guilty during a remote arraignment |qbe| nmz| che| hlc| bmi| fci| rjw| xur| dwk| vws| pot| sgm| vmh| nvu| ubm| msr| vma| fcu| dsj| kdp| weq| mhd| qpd| bbo| nzs| pyc| bml| ybv| xzc| clu| ugg| qjs| srz| nse| mos| kei| etj| nax| zxs| wgq| mvf| phe| ojm| dvo| jpd| pqb| edq| ulg| ijj| gse|